title: Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM.
abstract: OBJECTIVE
  We investigated whether inhibition of endogenous angiotensin II signaling reduces the recurrence rate of atrial fibrillation (AF) in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.
  
  
  BACKGROUND
  Structural and electrical remodeling contribute to AF. Previous experimental studies have implicated the angiotensin II signaling pathway in this process, and recent clinical evidence supports a beneficial effect of inhibiting angiotensin II activity.
  
  
  METHODS
  Using the AFFIRM database, we retrospectively identified a cohort of patients randomized to the rhythm-control arm who were in sinus rhythm. Exposure to angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors (ANGI) was determined, and the time to first recurrence of AF was compared between ANGI users and nonusers.
  
  
  RESULTS
  The study cohort included 732 patients not taking ANGI through the initial 2-month follow-up and 421 patients taking ANGI during this time. Patients in the ANGI group more likely had hypertension, diabetes, coronary artery disease, and congestive heart failure compared to patients not taking ANGI. Risk of AF recurrence in the ANGI treatment group did not differ from the risk observed in patients not taking the drugs (hazard ratio [HR] = 0.91, 95% confidence interval [CI] = 0.77-1.09). However, in patients with congestive heart failure or impaired left ventricular function, ANGI use was associated with a lower risk of AF recurrence.
  
  
  CONCLUSIONS
  This analysis provides evidence that ANGI use may be beneficial in some patient subgroups with AF and underscores the need for randomized clinical trials defining more fully the role of angiotensin II inhibition in treating AF.
authors.affiliation: Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA. kathy.murray@vanderbilt.edu
authors.forename: Katherine T
authors.initials: KT
authors.lastname: Murray
authors.forename: Jeffrey N
authors.initials: JN
authors.lastname: Rottman
authors.forename: Patrick G
authors.initials: PG
authors.lastname: Arbogast
authors.forename: Lynn
authors.initials: L
authors.lastname: Shemanski
authors.forename: R Kirby
authors.initials: RK
authors.lastname: Primm
authors.forename: W Barton
authors.initials: WB
authors.lastname: Campbell
authors.forename: Allen J
authors.initials: AJ
authors.lastname: Solomon
authors.forename: Jeffrey E
authors.initials: JE
authors.lastname: Olgin
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Wilson
authors.forename: John P
authors.initials: JP
authors.lastname: Dimarco
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Beckman
authors.forename: George
authors.initials: G
authors.lastname: Dennish
authors.forename: Gerald V
authors.initials: GV
authors.lastname: Naccarelli
authors.forename: Wayne A
authors.initials: WA
authors.lastname: Ray
mesh_terms: D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D019992:Databases as Topic; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D008297:Male; D016032:Randomized Controlled Trials as Topic; D012008:Recurrence; D012189:Retrospective Studies; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000806:Angiotensin-Converting Enzyme Inhibitors